Effect of fludarabine and arabinosylcytosine on multidrug resistant cells

Haematologica

Volumn 82, Issue 2, 1997, Pages 143-147

  Michelutti, Angela ^a   Michieli, Mariagrazia ^a   Damiani, Daniela ^a   Melli, Cristina ^a   Ermacora, Anna ^a   Grimaz, Stefania ^a   Candoni, Anna ^a   Russo, Domenico ^a   Fanin, Renato ^a   Baccarani, Michele ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Acute leukemia; Anthracycline; Arabinosylcytosine; Chemotherapy; Fludarabine; Multidrug resistance

Indexed keywords

CYTARABINE; FLUDARABINE;

ACUTE LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; TUMOR CELLS, CULTURED; VIDARABINE;

EID: 17144441806     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Beck WT. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II and other factors. Cancer Treat Res 1990; 17(suppl. A):11-20.
2. Kaye SB. The multidrug resistance phenotype. J Cancer 1988; 58:691-4.
3. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. P-glycoprotein in pathology, the multidrug resistance gene family in humans. Human Pathol 1990; 21:34-48
4. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54:357-61.
5. Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993; 53:1475-9.
6. Bassan R, Barbui T. Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica 1995; 80:82-90.
7. Capizzi RL, White JC, Powell BL, Perrino F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol 1991; 28:54-69.
8. Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 1990; 4:95-9.
9. Rustum YM, Preisler HD. Correlation between leukemic cell retention of 1-β-D-Arabinofuranosylcytosine 5′-Triphosphate and response to therapy. Cancer Res 1979; 39:42-9.
10. Brockman RW, Schabel JRFM, Montgomery JA. Biologic activity of A-β-D-arabinofuranosyl-2-fluoradenine, a metabolically stable analog of 9-β-D-arabinofurosyladenine. Biochem Pharmacol 1977; 26:2193-8.
11. Plunkett W, Chubbs S, Alexander L, et al. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine in human lymphoid cells. Cancer Res 1980; 40:2349-54.
12. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86:2463-74.
13. Tseng WC, Derse D, Cheny YC, et al. In vitro activity of 9-β-D-arabinofuranosyl-2-fluoro-adenine and the biochemical actions of its triphosphates on DNA polymerases and ribonucleotide reductase from HCLa cells. Mol Pharmacol 1982; 21:474-80.
14. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine: a mechanism of toxicity. J Biol Chem 1990; 265:1661-7.
15. Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosyl cytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lympnocytic leukemia: implication for combination therapy. Blood 1989; 74:2070-5.
16. Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 1992; 52:897-903.
17. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11:116-24.
18. Tosi P, Visani G, Ottaviani E, Manfroi S, Zinzani PL, Tura S. Fludarabine+Ara-C+G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994; 8:2076-82.
19. Keating MJ, Estey E, Kantarjian H, et al. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia 1992; 6(Suppl. 2):78-80.
20. Visani G, Tosi P, Zinzani PL, et al. FLAG (Fludarabine+High-dose Cytarabine+G-CSF): an effective and tolerable protocol for the treatment of "poor risk" acute myeloid leukemias. Leukemia 1994; 8:1842-6.
21. Suki S, Kantarjian H, Gandhi V, et al. Fludarabine and Cytosine Arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 1993; 72:2155-60.
22. Gandhi V. Fludarabine for treatment of adult acute myelogenous leukemia. Leuk Lymphoma 1993; 11(suppl. 2):7-13.
23. Michieli M, Damiani D, Michelutti A, et al. Screening of multidrug resistance in leukemia: cell reactivity to MRK-16 correlates with anthracycline retention and sensitivity of leukemic cells. Leuk Lymphoma 1996; 23:99-105.
24. Michelutti A, Michieli M, Damiani D, et al. Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia. Haematologica 1994; 79:200-4.
25. Michieli M, Michelutti A, Damiani D et al. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives. Leuk Lymphoma 1993; 9:255-64.
26. Michieli M, Damiani D, Michelutti A, et al. P170-dependent multidrug resistance. Restoring full sensitivity to Idarubicin with Verapamil and Cyclosporin A derivatives. Haematologica 1994; 79:119-26.
27. Michieli M, Damiani D, Michelutti A, et al. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin. Haematologica 1996; 81:296-302.
28. Pieters R, Huismans DR, Leyva A, et al. Comparison of a rapid automated tetrazolium based (MTT)-assay with a dye exclusion assay for chemosensitivity testing in childhood leukemia. Br J Cancer 1989; 59:217-20.
29. Michieli M, Damiani D, Geromin A, et al. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Heamatol 1992; 48:87-92.
30. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlation with treatment outcome and in vitro drug sensitivity. Blood 1991; 78:586-92.
31. Campos L, Guyotat D. Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79:473-6.
32. Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995; 9:1661-6.
33. Ino T, Miyazaki H, Isogai M, et al. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia 1994; 8:1492-9.
34. Wood P, Burgess R, MacGregor A, Liu Yin JA. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994; 87:509-14.
35. Zöchbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994; 8:974-7.
36. Michieli M, Damiani D, Michelutti A. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica 1994; 79:500-7.
37. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 98:155-99.
38. Sonneveld P. Reversal of multidrug resistance in acute myeloid leukaemia and other haematologtcal malignancies. Eur J Cancer 1996;32A:1062-9.
39. Gottesman MG, Pastan I. Clinical trials of agents that reverse multidrug-resistance. J Clin Oncol 1989; 7:409-11.
40. Figueredo A, Arnold A, Goodyear M, et al. Addition of Verapamil and Tamoxifen to the initial chemotherapy of small cell lung cancer. Cancer 1990; 65:1895-902.
41. Raderer M, Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer 1993; 72:3553-63.
42. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989; 9:3808-20.
43. Pileri SA, Sabattini E, Falini B, et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991; 19:131-40.
44. Damiani D, Michieli M, Michelutti A, et al. Expression of multidrug resistance gene (mdr-1) in human normal leukocytes. Haematologica 1993; 78:12-7.
45. Drach D, Zhao S, Drach J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992; 80:2729-34.
46. Chaudhary PM, Roninson I. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66:85-94.
47. Hitchins RN, Harman DH, Daye RA, Bell DR. Identification of a multirug resistance asociated antigen (P-glycoprotein) in normal human tissues. Eur J Cancer Clin Oncol 1988; 24:449-54.
48. Sugawara I, Kataoka I, Morishita Y, et al. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK-16. Cancer Res 1988; 48:1926-9.